Teladoc Health, Inc.

NYSE:TDOC

Medical - Healthcare Information Services

Healthcare
$8.06 +2.57%

+$0.20 today

Market cap
$1.47B
Beta
2.14
P/E (TTM)
-8.1
EPS (TTM)
-$0.96
52W Low $4.40High $9.77

Volume 3.96M

Average 4.68M

TDOC Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Teladoc Health, Inc.NYSE: TDOC

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables grows, but more slowly than its trailing trend

Q1 FY2026 accounts receivables of $21M (cash outflow) rose 37.5% year over year, behind the +209.1% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 1.0% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Accounts receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +37.5% toward the trailing-twelve-month pace of +209.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21M-220.2% QoQ
Last fiscal yearDec 2025
$25.13M+6800.3% YoY
LTMMar 2026
$19.4M+209.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.5%——
1 year+6800.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
25.13M USD
Year-over-year change
+6800.3%

Accounts Receivables vs competitors

How TDOC compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +209.1% is the highest of 9, against a peer median of +34.6%.
  • Accounts receivables amounts to 0.8% of revenue for TDOC, versus a peer median of 2.7%.
TDOC Competitors
Accounts Receivables for TDOC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PGNYProgyny, Inc.LTM Jun 2026$53.11M USD-1291.9%-65.0%4.1%
NVCRNovoCure LimitedLTM Mar 2026$29.5M USD-6.9%—4.4%
TDOCTeladoc Health, Inc.LTM Mar 2026$19.4M USD+209.1%—0.8%
SDGRSchrödinger, Inc.LTM Sep 2026$12.31M USD-2.1%—4.6%
OMDAOmada HealthLTM Mar 2026$12.07M USD+71.3%+46.5%4.3%
PHRPhreesia, Inc.LTM Apr 2026$6.91M USD+177.6%-3.0%1.4%
OMCLOmnicell, Inc.LTM Mar 2026$4.99M USD+206.8%—0.4%
AZTAAzenta, Inc.LTM Sep 2026$4.42M USD+118.0%-49.6%0.7%
PHVSPharvaris N.V.LTM Sep 2026€1.21M EUR-592.3%——
IMNMImmunome, Inc.LTM Sep 2026$0 USD———
EVOEvotec SELTM Mar 2026€0 EUR—-19.9%0.0%
Peer median (excluding TDOC) —+34.6%-19.9%2.7%

Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(428.79M)(13.66B)(220.37M)(1B)(200.32M)
Depreciation & Amortization219.62M267.78M348.72M382.84M363.12M
Deferred Income Tax41.8M(7.84M)(1.9M)(1.15M)(41.41M)
Stock-Based Compensation302.59M217.85M201.55M145.95M80.41M
Change in Working Capital(43.99M)(48.39M)11.64M(36.32M)1.08M
Accounts Receivables(11.17M)(49.06M)(10.25M)(375K)25.13M
Inventory(19.49M)14.8M24.1M(9.75M)399K
Accounts Payables1.19M1.88M(4.19M)(10.37M)11.45M
Other Working Capital(14.51M)(16.01M)1.99M(15.83M)(35.9M)
Other Non-Cash Items102.76M13.42B10.38M803.59M91.48M
Operating Cash Flow193.99M189.29M350.02M293.68M294.36M
Capital Expenditures(8.53M)(16.48M)(156.35M)(10.79M)(8.89M)
Acquisitions (Net)(78.66M)000(81.9M)
Purchases of Investments00000
Sales of Investments60.9M2.51M00740K
Other Investing Activities8.72M2.51M1K(113.26M)(175.95M)
Investing Cash Flow(72.98M)(167.74M)(156.35M)(124.05M)(266M)
Debt Repayment(914K)(3.15M)00(550.63M)
Common Stock Issued42.59M12.39M11.13M8.31M3.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(730K)(2.74M)(278K)(2K)(4.11M)
Financing Cash Flow40.95M6.5M10.85M8.31M(551.65M)
Effect of Forex Changes(1.8M)(3.34M)965K(3.29M)6.06M
Net Change in Cash160.16M24.7M205.49M174.65M(517.24M)
Free Cash Flow185.46M172.81M193.67M282.89M285.46M

Teladoc Health, Inc.

NYSE:TDOC

Intrinsic Alpha fair value

Locked

Current Price

$8.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.